On the potential of oncolytic virotherapy for the treatment of canine cancers

Amy L MacNeill
Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA

Abstract: Over 6 million dogs are diagnosed with cancer in the USA each year. Treatment options for many of these patients are limited. It is important that the veterinary and scientific communities begin to explore novel treatment protocols for dogs with cancer. Oncolytic viral therapy is a promising treatment option that may prove to be relatively inexpensive and effective against several types of cancer. The efficacy of oncolytic virus therapies has been clearly demonstrated in murine cancer models, but the positive outcomes observed in mice are not always seen in human cancer patients. These therapies should be thoroughly evaluated in dogs with spontaneously arising cancers to provide needed information about the potential effectiveness of virus treatment for human cancers and to promote the health of our companion animals. This article provides a review of the results of oncolytic virus treatment of canine cancers.

Keywords: oncolytic virus, cancer, canine

Introduction
There is a growing interest in using viruses to eliminate cancers. There are many excellent articles that review the current use of oncolytic viruses in human clinical trials. Very recently, there have been enough positive results from human clinical trials that emerging oncolytic viral therapies have been showcased by popular media programs. A report by the Home Box Office (HBO) series Vice focused on trials using recombinant poxvirus, measles virus, and lentivirus to treat a variety of cancers. The Columbia Broadcasting System (CBS) news show 60 Minutes aired interviews with researchers and patients involved in trials using a modified poliovirus to treat patients with glioblastoma. Hopefully, this type of press will spur interest in funding additional oncolytic virus studies.

One hundred and eleven years of viral cancer therapy
The idea of using pathogens to eliminate neoplastic cells is not a new one. It began in the early 20th century with a report of remission of leukemia in a woman who had acquired a respiratory infection (likely influenza). In the 1950s and 1960s, interest in oncolytic viruses reemerged, leading to some promising human clinical trials including the use of adenovirus to treat cervical carcinoma. However, during this time period, the ethics of how patients were recruited into clinical trials were highly questionable and oncolytic virus studies were stopped. Since then, ethical guidelines for human clinical trials have been established and there have been critical scientific advances in molecular biology, cancer biology, immunology, and pathogenesis of infectious diseases. These developments have enabled scientists to design recombinant viruses that are
no longer pathogenic, but demonstrate improved targeting of neoplastic cells, enhanced oncolytic properties, and/or desirable immunologic effects. In 2005, People’s Republic of China approved a conditionally replicating adenovirus for the treatment of human head and neck squamous cell carcinoma. This oncolytic viral therapy may be beneficial, but its efficacy likely can be improved and additional types of cancers can be targeted.

Several clinical cancer trials are ongoing to evaluate the effectiveness of attenuated viruses in humans, but trials in canine cancer patients are rare. Genetically altered viruses currently being tested in humans include adenovirus, coxsackievirus, herpes simplex virus, lentivirus, measles virus, parvovirus, poliovirus, reovirus, retrovirus, and vaccinia virus (VACV). Newcastle disease virus, myxoma virus (MYXV), and others are actively being studied in murine cancer models. Unfortunately, many of the initial oncolytic viral therapies that were successful at clearing xenografts in murine tumor models failed to significantly induce remission in humans. This may be due to the fact that there are several aspects of spontaneous oncogenesis that cannot be repeated in murine tumor models. For example, the tumor microenvironment in a spontaneously arising neoplasm is very complex and involves modifications of the local vasculature and extracellular matrix that are not recapitulated in xenografts. Also, alterations in the immune system of cancer patients that allow for tumorigenesis to occur are not a component of murine xenograft models.

The importance of clinical trials in dogs with cancer
To continue to improve the efficacy of new cancer therapies, it is imperative that scientists begin to utilize cancer models which recapitulate the tumor microenvironment and the immunotolerance known to occur during oncogenesis. Spontaneous tumors of dogs are beginning to be recognized as an important model of human cancer that can meet these criteria. Additionally, dogs are outbred and their genetics are well classified, dogs and humans have similar exposure to environmental factors that affect tumorigenesis, and the biologic behavior of several canine cancers parallels the clinical disease course observed in humans. In the author’s opinion, dogs with spontaneously arising cancers are an underutilized population of patients that are excellent animal models of human cancers and simultaneously could benefit from adjunctive treatment with an appropriate oncolytic virus. Just as data from canine clinical trials could improve responses to oncolytic viruses in human cancer patients, information learned from human clinical trials could be used to develop effective treatment protocols in canine cancer patients.

Key attributes of viral cancer therapy
Initially, it was thought that direct lysis of cancer cells by a virus would be the primary mechanism for the antineoplastic effects of a virus therapy, hence the term “oncolytic virus therapy”. Although virus-induced cancer cell death does occur, there is a large amount of evidence that indicates the immune response to the virus is a key component of an effective antineoplastic virus therapy. The ideal oncolytic virus should destroy tumor cells throughout the body and induce antitumor immunity without damaging healthy cells. Indeed, safety is a key concern with oncolytic viruses, particularly when used in immunosuppressed patients. Safety may be enhanced by using nonpathogenic, genetically stable virotherapeutics derived from wild-type viruses that do not cause severe disease and lack the ability to integrate into the patients’ DNA.

Tumor specificity of oncolytic viruses
Increasing the tumor specificity of a virotherapeutic also can enhance its safety. Interestingly, some of the common cellular pathway alterations found in neoplasms allow viruses to productively and selectively infect tumor cells (Figure 1). Several tumor cells have mutations in key components of intracellular signaling pathways which block apoptosis and/or promote proliferation, making them susceptible to viral infection. Other tumor cells lack adequate antiviral interferon responses that prevent virus replication in noncancerous cells. Some viruses are inherently tumor-selective or can be genetically altered to improve tumor specificity. For example, in many oncolytic adenoviruses, the viral E1a gene is disrupted and/or the E1b-55K gene is deleted so that the viruses can only replicate in cells with defective retinoblastoma or p53 pathways, respectively. Also, several oncolytic VACVs have the viral thymidine kinase gene deleted, which limits virus replication to actively dividing cells. Additionally, oncolytic viruses may be designed to contain tumor-specific promoter elements that only permit replication of the virus in tumor cells.

The immune response to virus therapy
Oncolytic virotherapy has the potential benefit of altering the tumor microenvironment enough to break existing tumor immunotolerance (Figure 2). Failure of the immune system to recognize tumor cells may be due to a paucity of stimulated immune cells infiltrating the tumor and/or
masking of tumor antigens. Aberrant cytokine patterns in the tumor microenvironment may severely limit an antitumor immune response. Additionaly, regulatory T-cells and myeloid-derived suppressor cells may be present in increased numbers in cancer patients. These immunologic hurdles can be overcome by oncolytic viral therapy if infected tumor cells express viral antigens that trigger a fully functional cellular immune response and alter cytokine production to promote infiltration of immune cells. Ideally, when the cellular immune response lyases infected tumor cells and presents viral antigens to cells of the immune system, hidden tumor antigens that the immune system can respond to will also be exposed. This would lead to clearance of the virus by the immune system and concurrent amplification of an antitumor immune response. Indeed, oncolytic viruses that eliminate xenografts in murine cancer models have been shown to induce an antitumor immune memory that prevents re-engraftment of the tumor cells.

Oncolytic viruses as therapeutic vectors

One of the most powerful attributes of oncolytic viral therapy is the ability to design viruses that express exogenous proteins. Viral expression of tumor-associated antigens, cytokines, or chemokines could promote antitumor immune responses that eliminate tumor cells. Intratumoral injection of an oncolytic poxvirus expressing granulocyte–monocyte colony-stimulating factor (GM-CSF) caused regression of the tumor and metastatic lesions. In this study, virus was not recovered from the metastatic lesions but T-cell infiltration was documented. Furthermore, tumor angiogenesis can be limited and tumor growth suppressed by recombinant viruses expressing vascular endothelial growth factor (VEGF) inhibitors. Additionally, genetically altered oncolytic viruses can be used to target chemotherapeutics to the tumor and minimize the systemic effects of the drugs.

Oncolytic virus treatment of canine cancers

Many publications indicate that oncolytic viruses can replicate and lyse canine cancer cells in culture (Table 1). Murine xenograft models of canine cancers also have been successfully treated with oncolytic viruses (Table 2). A few publications have used replication-deficient adenoviruses as vectors for gene therapy in canine models (Table 3). Viruses that are replication deficient are actually using a gene therapy approach to cancer treatment, rather than functioning as true oncolytic viruses. These studies are included in this review because they demonstrate the effective use of viruses as therapeutic vectors in canine cancer patients.
<table>
<thead>
<tr>
<th>Virus family</th>
<th>Oncolytic virus</th>
<th>Canine cell type</th>
<th>Outcome</th>
<th>Authors, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoviridae</td>
<td>CRAd5</td>
<td>Osteosarcoma</td>
<td>Small amount of virus produced</td>
<td>Ternovoi et al, 2005</td>
</tr>
<tr>
<td></td>
<td>CRAd5 + CAV2 knob</td>
<td>Osteosarcoma</td>
<td>Large amount of virus produced</td>
<td>Le et al, 2006</td>
</tr>
<tr>
<td></td>
<td>CRAd + p53</td>
<td>Osteosarcoma ChOS, OOS Mammmary adenocarcinoma CHMp, CIPm, CNMm</td>
<td>Inhibited cell growth</td>
<td>Yazawa et al, 2003</td>
</tr>
<tr>
<td></td>
<td>OC-CAVE1</td>
<td>Osteosarcoma</td>
<td>Induced cell death</td>
<td>Hemminki et al, 2003</td>
</tr>
<tr>
<td></td>
<td>CAV2 + hyaluronidase</td>
<td>Osteosarcoma Abrams, D17 Melanoma 7CM98, CMLI</td>
<td>Supported virus growth</td>
<td>Laborda et al, 2014</td>
</tr>
<tr>
<td>Paramyxoviridae</td>
<td>Canine distemper virus</td>
<td>Lymphoma CLL-I 390, CLGL-90, 17-71 Lymphocytes and neutrophils from dogs Neoplastic lymphocytes from dogs</td>
<td>Contain CD150 mRNA</td>
<td>Suter et al, 2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Osteosarcoma</td>
<td>Contain CD46 and CD150 mRNA Supported virus infection No detectable CD46 or CD150 mRNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mammary adenocarcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melanoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poxviridae</td>
<td>Vaccinia virus</td>
<td>Mammary tumor ZMT3, MTH52c Primary soft tissue sarcoma STSA-1 Prostatic carcinoma DT08/40</td>
<td>Increased cell death</td>
<td>Gentschev et al, 2009</td>
</tr>
<tr>
<td></td>
<td>GLV-1h68</td>
<td>STSA-1</td>
<td></td>
<td>Gentschev et al, 2010</td>
</tr>
<tr>
<td></td>
<td>Vaccinia viruses</td>
<td>LIVP 1.1.1 and 6.1.1 Primary soft tissue sarcoma STSA-1</td>
<td></td>
<td>Gentschev et al, 2012</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Melanoma</td>
<td></td>
<td>Gentschev et al, 2013</td>
</tr>
<tr>
<td></td>
<td>LIVP 6.1.1</td>
<td>CHAS Osteosarcoma DI 7 Prostatic carcinoma DT08/40</td>
<td></td>
<td>Patil 2012</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Primary soft tissue sarcoma STSA-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GLV-1h109</td>
<td>STSA-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virus Type</td>
<td>Disease</td>
<td>Tumor Type</td>
<td>Effect</td>
<td>References</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>------------</td>
<td>--------</td>
<td>------------</td>
</tr>
</tbody>
</table>
| Vaccinia virus | DT08/40 | Prostatic carcinoma | Increased cell death | Adelfinger et al, 2015
| GLV-5b451 | Mammary tumor MTH52c, ZMTH3; Prostatic carcinoma CT1258; Primary soft tissue sarcoma ST5A-1 | | | |
| Vaccinia virus vvdd + CD40L | Osteosarcoma Abrams Prostatic carcinoma ACE-I | Recombinant protein expression | Autio et al, 2014
| Myxoma virus MYXVΔserp2 | Hemangiosarcoma Den Transitional cell carcinoma Biley Primary hemangiosarcoma HSA-1 Primary soft tissue sarcoma ST5A-1 | Increased apoptosis of infected cells | Urbasic et al, 2012
| Reoviridae Dearing strain of reovirus serotype 3 | Mast cells Primary cells Mast cell tumor VIMC, CoMS, CM-MC, HRMC Lymphoma CL-1, UL-1, CLGL-90, Nody-1, Ema, CLK, GL-1, 17-71, CLBL-1, CLC Melanoma CMeC1, CmeC2, KMec, LMeC, CMGD2, CMGD5 Mammary carcinoma CiPp, CiPm, CTBp, CTBm, CHMp, CHMm, CNMm Osteosarcoma Abrams, D17, Gracie, MacKinley, Moresco | Increased apoptosis | Hwang et al, 2013
| | | Increased apoptosis in some cells | Hwang et al, 2013
| | | | Hwang et al, 2014
| | | | Igase et al, 2015
| Togaviridae Alphavirus VA7-EGFP | Osteosarcoma Abrams, D17 | Induced cell death | Autio et al, 2015
More importantly for oncolytic virus research, studies have been published that report the safety profiles of replicating MYXV, modified adenovirus, and attenuated vesicular stomatitis and Semliki Forest viruses in healthy dogs (Table 4).

Table 4 also summarizes the current studies using replicating oncolytic viruses in canine cancer patients.39 Clinical trials using oncolytic virotherapy in dogs are the next step toward advancing treatment options for dogs with cancer. Simultaneously, these studies may provide a more accurate predictive model of human response to virotherapy.

### Adenoviruses

**Adenovirus background**

Adenoviruses are one of a few types of oncolytic viruses that have been evaluated in dogs. These viruses are non-enveloped,

<table>
<thead>
<tr>
<th>Virus family</th>
<th>Oncolytic virus</th>
<th>Canine cell type</th>
<th>Outcome</th>
<th>Authors, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoviridae</td>
<td>CRAd5 + CAV2</td>
<td>Osteosarcoma</td>
<td>Recombinant protein expression</td>
<td>Le et al, 2006</td>
</tr>
<tr>
<td></td>
<td>CRAd + p53</td>
<td>Osteosarcoma</td>
<td>Inhibited tumor growth</td>
<td>Kanaya et al, 2011</td>
</tr>
<tr>
<td></td>
<td>OC-CAVe</td>
<td>Osteosarcoma</td>
<td>Improved outcome</td>
<td>Hemminki 2003</td>
</tr>
<tr>
<td></td>
<td>CAV2 + hyaluronidase</td>
<td>Osteosarcoma</td>
<td>Decreased tumor growth</td>
<td>Laborda et al, 2014</td>
</tr>
<tr>
<td>Poxviridae</td>
<td>Vaccinia virus</td>
<td>Mammary tumor</td>
<td>Decreased tumor burden</td>
<td>Gentschev et al, 2009</td>
</tr>
<tr>
<td></td>
<td>GLV-1h68</td>
<td>ZMTH3</td>
<td>Mild weight loss</td>
<td>Gentschev et al, 2010</td>
</tr>
<tr>
<td></td>
<td>LIVP 1.1 and 6.1.1</td>
<td>Primary soft tissue sarcoma</td>
<td>Decreased tumor burden</td>
<td>Gentschev et al, 2012</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Prostatic carcinoma</td>
<td>Decreased tumor burden</td>
<td>Gentschev et al, 2013</td>
</tr>
<tr>
<td></td>
<td>LIVP 1.1</td>
<td>DT08/40</td>
<td>Decreased tumor burden</td>
<td>Patil 2012</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Primary soft tissue sarcoma</td>
<td>Decreased tumor burden</td>
<td>Adelfinger et al, 2015</td>
</tr>
<tr>
<td></td>
<td>GLV-1h109</td>
<td>Prostatic carcinoma</td>
<td>Decreased tumor burden</td>
<td>Hwang et al, 2013</td>
</tr>
<tr>
<td></td>
<td>GLV-5b451</td>
<td>Prostate carcinoma</td>
<td>Decreased tumor growth</td>
<td>Auto et al, 2014</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Mast cell tumor</td>
<td>Decreased tumor growth</td>
<td>Hwang et al, 2013</td>
</tr>
<tr>
<td></td>
<td>vvd</td>
<td>T-cell lymphoma</td>
<td>Decreased tumor growth</td>
<td>Hwang et al, 2014</td>
</tr>
</tbody>
</table>

### Table 3 Adenovirus vectors tested in dogs with and without spontaneous tumors

<table>
<thead>
<tr>
<th>Virus vector</th>
<th>Dogs (n)</th>
<th>Route</th>
<th>Outcome (n)</th>
<th>Authors, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Ad6 (two constructs)</td>
<td>Healthy (3–6)</td>
<td>Intramuscular</td>
<td>No detrimental effects</td>
<td>Peruzzi et al, 2010</td>
</tr>
<tr>
<td>Ad6-dTERT</td>
<td>Lymphoma (14)</td>
<td>Intramuscular</td>
<td>Prolonged survival time</td>
<td>Peruzzi et al, 2010</td>
</tr>
<tr>
<td>Ad-iFNγ</td>
<td>Astrocytoma (1)</td>
<td>Intratumoral</td>
<td>Prolonged survival time</td>
<td>Pluhar et al, 2010</td>
</tr>
<tr>
<td>AdCD40L</td>
<td>Oral melanoma (1)</td>
<td>Intratumoral</td>
<td>Complete remission (2)</td>
<td>von Euler et al, 2008</td>
</tr>
<tr>
<td></td>
<td>Dermal melanoma (1)</td>
<td>Intratumoral</td>
<td>Complete remission (5)</td>
<td>Westberg et al, 2013</td>
</tr>
<tr>
<td></td>
<td>Melanoma (19)</td>
<td>Intratumoral</td>
<td>Partial remission (8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIMC, CoMS</td>
<td>Intraocular</td>
<td>Stable disease (4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CL-I</td>
<td>Intraocular</td>
<td>Progressive disease (2)</td>
<td></td>
</tr>
</tbody>
</table>
linear, double-stranded DNA viruses. Most adenoviruses cause mild upper respiratory tract infections, including canine adenovirus (CAV) 2. Other adenoviruses cause severe disease. For example, CAV1 is the cause of infectious canine hepatitis. Attenuated forms of CAV2 have safely been used for many years as vaccines to protect dogs against CAV1. This has helped establish the use of CAV2 as an oncolytic virus in dogs.

Adenoviruses are classified into serotypes that have varied cell tropism. The cell tropism of adenoviruses can be modified to direct infection to cell types lacking the natural viral receptors through transductional targeting or genetic modification. Adenoviruses are promising as vectors for expression of exogenous antigens; however, their ability to maintain gene expression in cells is linked to their ability to evade the immune system and prevent cell death during viral replication, attributes which may make them less ideal as oncolytic virus therapies. Nonetheless, adenoviruses have been shown to be effective oncolytic viruses in many cancer models.

### Adenovirus effects on canine cancer cell cultures and xenografts

Many adenovirus constructs designed to be used in clinical trials to treat dogs with cancer were first tested in canine cell cultures and murine xenograft models of canine cancer. Conditionally replicating human adenovirus (CRAd) 5 was shown to replicate in several canine cancer cell lines and primary canine cancer cell cultures, but the level of virus production is moderate in canine cells as compared to human cells. When functional components encoded by CAV2 were inserted genetically into CRAd5, virus replication in canine osteosarcoma cells was improved and increased expression of a reporter gene encoded by the virus was observed in a murine xenograft model of canine osteosarcoma. Similarly, a CRAd that expresses canine p53 inhibited the growth of canine cancer cells and tumors in two murine xenograft models of canine osteosarcoma.

### Table 4 Oncolytic viruses tested in dogs with and without spontaneous tumors

<table>
<thead>
<tr>
<th>Virus family</th>
<th>Virus</th>
<th>Dogs</th>
<th>Route</th>
<th>Outcome</th>
<th>Authors, year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoviridae</td>
<td>Recombinant Ad5</td>
<td>Healthy (6)</td>
<td>Prostatic (3)</td>
<td>Transgene expression in prostate</td>
<td>Barton et al, 2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic (3)</td>
<td>Neutrophilia, pancreatitis, hepatitis</td>
</tr>
<tr>
<td></td>
<td>CRAd with prostate-specific promoter intended for use in humans</td>
<td>Healthy (4)</td>
<td>Prostatic</td>
<td>Virus in prostate, vas deferens, iliac lymph nodes, bladder, heart, and liver</td>
<td>Lu et al, 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Transgene expression in prostate only</td>
<td></td>
</tr>
<tr>
<td>OC-CAVE,</td>
<td>Healthy (3)</td>
<td>Intravenous</td>
<td>Neutropenia</td>
<td>Virus in feces, urine, liver, and spleen</td>
<td>Smith et al, 2006</td>
</tr>
<tr>
<td>CAV2 + hyaluronidase</td>
<td>Osteosarcoma (2)</td>
<td>Intratumoral</td>
<td>Surgical removal (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic carcinoma (1)</td>
<td></td>
<td>Partial remission (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mast cell tumor (1)</td>
<td></td>
<td>Progressive disease (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fibrosarcoma (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adenoma (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poxviridae</td>
<td>Vaccinia virus</td>
<td>Solid subcutaneous tumors</td>
<td>Unknown</td>
<td>Completed trial</td>
<td>Szalay, 2014,</td>
</tr>
<tr>
<td></td>
<td>LIVP 6.1.1</td>
<td></td>
<td></td>
<td></td>
<td>Unpublished data</td>
</tr>
<tr>
<td></td>
<td>Vaccinia virus</td>
<td>Healthy (2)</td>
<td>Unknown</td>
<td>No detrimental effects</td>
<td>Hemminki, 2015</td>
</tr>
<tr>
<td></td>
<td>wvd + CD40L</td>
<td>Incurable solid tumors</td>
<td></td>
<td>Ongoing trial</td>
<td>Unpublished data</td>
</tr>
<tr>
<td></td>
<td>Myxoma virus</td>
<td>Healthy</td>
<td>Subcutaneous</td>
<td>No detrimental effects</td>
<td>Görski et al, 1994</td>
</tr>
<tr>
<td></td>
<td>Varied strains</td>
<td></td>
<td>Intramuscular</td>
<td></td>
<td>Bull and Dickinson, 1971</td>
</tr>
<tr>
<td></td>
<td>Myxoma virus</td>
<td>Mast cell tumor (1)</td>
<td>Intratumoral</td>
<td>Surgical removal (1)</td>
<td>MacNeill, 2015,</td>
</tr>
<tr>
<td></td>
<td>MYXY3sserp2</td>
<td>Soft tissue sarcoma (10)</td>
<td></td>
<td>Ongoing trial</td>
<td>Unpublished data</td>
</tr>
<tr>
<td>Rhabdoviridae</td>
<td>Vesicular stomatitis virus</td>
<td>Healthy (5)</td>
<td>Intravenous</td>
<td>Maximum tolerated dose =10^10 TCID&lt;sub&gt;50&lt;/sub&gt;</td>
<td>LeBlanc et al, 2013</td>
</tr>
<tr>
<td></td>
<td>VSV-IFN5-NIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Togaviridae</td>
<td>Alphavirus</td>
<td>Healthy (2)</td>
<td>Intravenous</td>
<td>No detrimental effects</td>
<td>Autio et al, 2015</td>
</tr>
</tbody>
</table>

Note: TCID<sub>50</sub> = tissue culture infectious dose that produces cytopathic effects in 50% of the cells.
in canine osteosarcoma cultures and improved outcome in a murine xenograft model of canine osteosarcoma. When osteosarcoma cells were used as carriers to deliver this virus intravenously, viral expression in the liver was minimized and tumor growth in murine models of canine osteosarcoma was inhibited.

Adenovirus safety profiles in healthy dogs
The safety profiles of several recombinant adenoviruses were tested in healthy dogs before being used in cancer patients. As preliminary information for human clinical trials, a replication-competent recombinant Ad5 was injected into the prostate or pancreas of dogs (three dogs per group). Very few data were collected following prostatic injection except to verify that transgene expression was observed in the prostate. Dogs with pancreatic injections developed neutrophilia, acute pancreatitis, and hepatitis. The safety of an adenovirus designed to express beta-galactosidase driven by a prostate-specific promoter can be implied from a recent study which injected 4.8x10^6 plaque-forming units (pfu) of virus into the prostate glands of healthy dogs. Viral DNA could be detected in several tissues 72 hours after injection, but transgene expression by the modified viruses was only observed in the prostate. As preliminary data for canine clinical trials, OC-CAVE1 was administered intravenously to six dogs; neutropenia was observed and virus was recovered from feces, urine, liver, and spleen at 96 hours after virus inoculation. More recently, replication-deficient Ad6 recombinant viruses were administered intramuscularly to groups of three to six dogs with no adverse effects.

Adenovirus clinical outcomes in cancer-bearing dogs
Clinical trials using adenoviruses to treat dogs with cancer have shown promising results with few side effects. Both replication-deficient adenoviruses and oncolytic adenoviruses have been studied in cancer-bearing dogs.

Adenovirus vectors
A replication-deficient Ad5 expressing CD40 ligand (AdCD40L) was designed to target the virus to cells expressing αvβ3 integrin as a means of inhibiting tumor angiogenesis. This virus was injected intratumorally into a dog with stage III oral melanoma and a dog with a melanoma on his eyelid; tumor resolution was observed in both patients. Additionally, promising results were reported in 19 cases of canine melanoma treated with intratumoral AdCD40L followed by either surgery or immunotherapy. Lymphocyte infiltration into the tumors was detected in eight of eleven dogs. Five of the 19 patients were reported to have complete disease remission, eight showed partial remission, four had stable disease, and only two experienced progressive disease.

One of the recombinant replication-deficient Ad6 viruses (Ad6-dTERT) tested in healthy dogs was used as an adjunct to chemotherapy and DNA vaccination in a clinical trial to treat dogs with high-grade B-cell lymphomas. Vaccinated dogs treated with the virus had significantly prolonged survival time compared to dogs treated with chemotherapy alone. Excellent results also were observed in a dog with astrocytoma following debulking surgery, intratumoral injection of an adenovirus expressing interferon-γ (Ad-IFNγ), and vaccination with a tumor homogenate.

Oncolytic adenovirus
A recombinant CAV2 virus with disruption of E1a, modification of cell receptor tropism, and hyaluronidase expression was evaluated in canine osteosarcoma and melanoma cell lines, murine xenograft models of canine osteosarcoma and melanoma, and in cancer-bearing dogs. Cell cultures that expressed the coxsackievirus and adenovirus receptor and expressed hyperphosphorylated retinoblastoma protein supported virus growth. When given 10^11 viral particles intravenously, healthy Balb/c mice experienced weight loss, severe thrombocytopenia, moderate lymphopenia, and mild increases in liver enzymes. Virus DNA could be isolated from most tissues. However, in nude mice bearing canine osteosarcoma and melanoma xenografts, a mild decrease in tumor growth and slight increase in survival time were observed following three intratumoral injections of 10^10 viral particles. No weight loss was detected in these mice. The treatment response to this virus varied in six dogs with cancer. Dogs were given at least one intratumoral injection of 10^12 viral particles. Tumor types that were treated included two cases of humoral osteosarcoma, a metastatic carcinoma involving the liver, a cutaneous mast cell tumor, a subcutaneous fibrosarcoma, and a sweat gland adenoma of the prepuce. Of these six cases, four dogs (with osteosarcomas, mast cell tumor, and fibrosarcoma) experienced swelling or bleeding at the site of virus injection. No treatment response was observed in patients with osteosarcoma or metastatic carcinoma. The dog with a mast cell tumor developed disseminated intravascular coagulopathy. However, positive outcomes were seen in the patient with fibrosarcoma (tumor removal following virus therapy) and the patient with a sweat gland adenoma (partial remission for 6 months).
Paramyxoviruses

Paramyxoviruses, including measles virus and canine distemper virus, have been tested in canine cancer cells. Paramyxoviruses are negative-stranded RNA viruses that induce syncytia formation in the cells they infect. These viruses infect and deplete lymphocytes. If constructed correctly, they may be effective treatments for lymphoma. Suter et al demonstrated that canine lymphoid cell lines and lymphocytes and polymorphonuclear cells isolated from healthy dogs contain mRNA which encodes the CD150 receptor needed for measles virus and canine distemper virus entry. Neoplastic canine lymphocytes isolated from dogs with lymphoma also contain mRNA for a second virus receptor, CD46. Importantly, canine distemper virus could infect some canine lymphoid cell lines and neoplastic lymphoid cells. No detectable mRNA for either receptor was found in canine osteosarcoma or melanoma cells.24

Poxviruses

Poxvirus background

Poxviruses have many attributes that make them excellent oncolytic viruses. Unlike many oncolytic viruses, poxviruses do not require a specific cellular receptor to infect cells.55 However, due to their large size, they naturally target neoplasms where new leaky vessels are being formed.32 Poxviruses are enveloped, double-stranded DNA viruses with genomes that replicate with high fidelity and allow for insertion of up to 25 kb of contiguous DNA, making them excellent vectors for exogenous protein expression.59 Poxviruses have their own replication machinery and remain in the cytoplasm of infected cells, so recombination of viral DNA into the host DNA does not occur and gene transcription begins immediately upon entering the host cell. Additionally, poxvirus virions are released from infected cells before the cells are lysed, allowing for efficient spread of virus to neighboring cancer cells.22 Importantly, poxviruses elicit a strong cell-mediated immune response and are ultimately cleared from the body by the humoral immune system, preventing poxviruses from causing latent or recurrent infection.60–63

VACV

VACV is the poxvirus most frequently used in oncolytic virotherapy and was the vaccine used to eradicate smallpox. Wild-type VACV causes mild-to-moderate disease in several species including humans and mice. Genetic manipulation of VACV has produced attenuated viruses with improved targeting of malignant cells and antitumor effects.15,64–67 Recombinant VACVs have shown promising results in many murine xenografts of human tumors and in some human clinical trials.

Several VACV constructs have been evaluated in canine cancer cell cultures and murine xenografts with canine tumors. Vaccinia viral recombinants with deletion of three viral genes have been shown to replicate in canine tumor cells and significantly decrease tumor volume in murine xenograft models of canine mammary tumors and soft tissue sarcoma.30,32,34 However, the virus caused mild weight loss and replicated at low levels in the liver, lung, spleen, and ovary of mice.32 A similar recombinant VACV encoding anti-VEGF was effective in reducing tumor volume in mice with canine soft tissue sarcoma or prostate carcinoma xenografts. Weight loss was not evident in these mice, but low levels of viral replication were detected in the liver, lung, kidney, and spleen of the mice with soft tissue sarcoma xenografts.33 Yet another modified VACV (LIVP 6.1.1) induced cell death in canine soft tissue sarcoma, melanoma, osteosarcoma, and prostate carcinoma cells. This virus effectively reduced tumor growth of canine soft tissue sarcoma and prostate carcinoma xenografts in mice.40 Similarly, when LIVP 6.1.1 was modified to express an anti-VEGF antibody, the new virus (GLV-5b451) induced cell death in canine soft tissue sarcoma, mammary tumor, and prostate carcinoma cells and reduced tumor growth of canine soft tissue sarcoma xenografts in mice.68

Variations of a recombinant VACV with deletion of genes encoding thymidine kinase and vaccinia growth factor (vvdd) have shown positive results in many murine xenograft models of human cancer.15,69,70 Recently, treatment with two intratumoral injections of 106 pfu of vvdd expressing luciferase (vvdd-luc) was effective at decreasing growth of a canine prostate tumor in nude mice.41 Another recombinant vvdd encoding human CD40L and the tdTomato reporter protein (vvdd-hCD40L-tdTomato) was shown to express recombinant proteins in canine osteosarcoma and prostate carcinoma cell lines. Incubation of 5×106 pfu of this virus with canine tumor biopsy sections resulted in viral transduction of cells in six of nine samples.41

Clinical trials using vvdd-hCD40L-tdTomato have been started at the University of Helsinki Faculty of Veterinary Medicine (Helsinki, Finland).41 Additionally, an unpublished clinical trial using a modified VACV to treat dogs with cancer was recently completed at Angel Care Cancer Center (Carlsbad, CA, USA). Results of that study are currently being analyzed; importantly, no adverse effects of virus inoculation were observed (AA Szalay, University of Würzburg, Germany, personal communication, August 2015).
MYXV
MYXV is a poxvirus that shares most of the attributes of VACV, but does not cause disease in any animal except the rabbit.\(^{51,71–77}\) MYXV infects tumor cells from several species, including dogs and cats.\(^{27,78–81}\) In rodent cancer models, MYXV treatment has eliminated some glioma xenografts, and reduced tumor burden in several types of xenografts and allografts.\(^{82–89}\)

A pilot study to assess the safety of MYXV deleted for serp2 (MYXVΔserp2) in dogs with soft tissue sarcomas is currently underway at the Colorado State University College of Veterinary Medicine and Biomedical Sciences (Fort Collins, CO, USA).

Prior to the study at Colorado State University, one canine cancer patient has been treated with MYXVΔserp2. The patient was a 13-year-old, female, spayed Labrador retriever with a subcutaneous mast cell tumor (grade II) that was treated by intratumoral inoculation with \(5\times10^7\) pfu of MYXVΔserp2. The poxvirus treatment was given once following biopsy of the mass and was repeated 5 days later. Eight days after the second treatment, the tumor was surgically resected. The biopsy taken prior to treatment contained large numbers of neoplastic mast cells (which appear deep purple with Giemsa staining). The tumor removed following treatment showed some necrosis and contained fewer mast cells and increased numbers of plasma cells as compared to the untreated biopsy sample (Figure 3). There were no clinical signs of disease following virus treatment and, 20 months postoperatively, the tumor has not recurred (MacNeill, unpublished data 2015).

![Figure 3](https://www.dovepress.com/)

**Figure 3** Images of a cutaneous mast cell tumor in a dog treated with an oncolytic virus. (A, B & C) Photographs of the gross lesion taken immediately prior to (A) the first recombinant myxoma virus (MYXVΔserp2) injection, (B) the second MYXVΔserp2 treatment, and (C) surgery. (D & E) Photomicrographs of a histologic section from the mast cell tumor prior to MYXVΔserp2 treatment [(D) hematoxylin and eosin (H & E) stain, 200x magnification; (E) Giemsa stain, 200x magnification]. (F & G) Photomicrographs of a histologic section from the mast cell tumor following two injections of MYXVΔserp2 [(F) H & E stain, 200x magnification; (G) Giemsa stain, 200x magnification]. sa stain, 200x magnification].

**Notes:** (D & E) A dermal mass was observed that was composed of round cells that stain deep purple with Giemsa stain, consistent with a mast cell tumor. (F and G) The surgically removed mass had fewer mast cells and more plasma cells than the untreated tumor.
Reovirus

Reoviruses are small, double-stranded RNA viruses that are ubiquitous and typically cause subclinical infections. Recently, the Mizuno laboratory (Yamaguchi, Japan) published three papers showing the potential of this virus for treatment of canine cancers. Hwang et al. found that canine mast cells and mast cell tumors are susceptible to apoptosis 72 hours following inoculation with 70 pfu of the Dearing strain of reovirus (serotype 3) per cell. In nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mast cell tumor xenografts, significant decreases in tumor growth were observed after intratumoral injection of 7x10^5 pfu; however, black tail syndrome occurred in a subset of the mice. Similarly, reovirus can induce apoptosis in a subset of canine lymphoma cell lines 72 hours postinoculation with 70 pfu per cell and can reduce tumor growth in a NOD/SCID xenograft model of canine T-cell lymphoma (CL-1 cells) following treatment with 10^7 pfu. Igase et al. also investigated the susceptibility of solid canine tumor cell lines to reovirus. They reported that apoptosis occurs 72 hours following inoculation with 70 pfu of reovirus per cell in a subset of melanoma and mammary carcinoma cell lines. Osteosarcoma cell lines were less susceptible to reovirus infection.

Togaviridae

Very recently, an attenuated Semliki Forest virus (VA7-EGFP) was shown to induce cell death in two canine osteosarcoma cell lines. Semliki Forest virus is a positive single stranded RNA virus classified in the Alphavirus genus of the Togavirus family. Although a virulent Semliki Forest virus strain caused neurologic disease in young dogs when administered by intraperitoneal or intracerebral injection, the attenuated form used in this study was safe in Beagles when given intravenously at 2 x 10^5 pfu.

Conclusion

Oncolytic viruses are exciting novel therapeutic options that could benefit dogs with cancer while providing better insight into which recombinant viruses will be most effective in human cancer patients. Conversely, as more oncolytic viruses enter human clinical trials, more oncolytic therapeutics may become available for use in companion animals. Prudent use of new oncolytic viruses will require an understanding of the biology of the viruses and the exogenous proteins they express. There is promise that oncolytic viruses will soon be a new, powerful treatment option for veterinary patients with cancer.

Disclosure

The author reports no conflicts of interest in this work.

References


